ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Reagan Goes On Record Against Smoking, Dietary Fat

April 22, 1988

In Brief: Senate Subcommittee Vote: $950 Million Plus training DeVita Needs New Clinical Assistant

July 21, 1978

CMS To Begin National Coverage Analysis Of Provenge

July 2, 2010

NIH Reauthorization Still Lingering, Bills ‘Tie Hands’ Of NCI Director

October 18, 1991

Other DCE Contract Recompetitions OKed

November 15, 1985

In Brief: Breast Cancer Tape ready; control Program Plans for 1978 Subject Of July 15 Meeting

June 17, 1977